Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: microscopic polyangiitis

Vasculitis Guidelines in Focus, Part 3: EGPA

Michael Putman, MD  |  September 14, 2021

In this third article in the series, we talk with Philip Seo, MD, MHS, about eosinophilic granulomatosis with polyangiitis (EGPA).

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:AAV FocusRheumEGPAeosinophilic granulomatosis with polyangiitis (EGPA)guidelineVasculitis

Vasculitis Guidelines in Focus, Part 2: ANCA-Associated Vasculitis

Michael Putman, MD  |  September 9, 2021

Sharon Chung, MD, MAS, discusses specific recommendations for the treatment and management of ANCA-associated vasculitis from the latest ACR Guideline.

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:AAV FocusRheumANCA-Associated VasculitisguidelineVasculitisVasculitis Foundation

Vasculitis Guidelines in Focus, Part 1: The Guideline Project

Michael Putman, MD  |  August 31, 2021

Sharon A. Chung, MD, MAS, director of the vasculitis clinic at the University of California, San Francisco, served as the principal investigator of the overall vasculitis guideline effort and talks about the process here.

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:GuidelinesVasculitisVasculitis Foundation

Sci Writers / shutterstock.com

FDA’s Arthritis Advisory Committee Narrowly Endorses Avacopan Approval

Ruth Jessen Hickman, MD  |  August 11, 2021

On May 6, the U.S. Food & Drug Administration’s (FDA’s) Arthritis Advisory Committee narrowly voted in support of avacopan, a C5a receptor inhibitor, for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Although the panelists were excited about the possibility of a steroid-sparing therapy, some raised questions about whether results from…

Filed under:ConditionsDrug UpdatesVasculitis Tagged with:ANCA-Associated VasculitisavacopanGlucocorticoids

The ACR/Vasculitis Foundation Release Three New Guidelines for Treatment of Vasculitis

From the College  |  July 9, 2021

ATLANTA—The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis. Vasculitis is a group of about 20 rare diseases that have inflammation of blood vessels in common, which can restrict blood flow and damage vital organs. The three guidelines cover…

Filed under:ConditionsVasculitis Tagged with:American College of Rheumatology (ACR)GuidelinesVasculitisVasculitis Foundation

Case Report: Child Develops Coronary Artery Aneurysms with GPA

Tryphina Adel Mikhail & Mary Bratovich Toth, MD  |  June 14, 2021

In September 2019, a previously healthy, 9-year-old white girl presented to the emergency department following two months of sinusitis and unexplained fever responsive to ibuprofen. She presented with anorexia; a 9 lb. weight loss; intermittent, nonbilious, nonbloody emesis; and occasional epistaxis with digital manipulation of the nose. Six weeks prior to admission, she had presented to…

Filed under:ConditionsPediatric ConditionsVasculitis Tagged with:case reportcoronary artery anuerysmsgranulomatosis with polyangiitisPediatricPediatric Rheum

ACR Quality of Care Committee Impresses with Its Recent Productivity

Ruth Jessen Hickman, MD  |  June 14, 2021

Over the past 18 months, the ACR’s Quality of Care (QOC) Committee has helped produce an impressive number of resources that will help rheumatologists deliver the best possible care. Working through specific projects supervised under its Criteria, Guideline, Guidance, and Quality Measure subcommittees, the QOC Committee has developed new sets of disease criteria, clinical guidelines,…

Filed under:Clinical Criteria/GuidelinesFrom the CollegeQuality Assurance/Improvement Tagged with:Classification CriteriaCommittee on Quality of Care

Study: Can Avacopan Replace Steroids in ANCA-Associated Vasculitis?

Ruth Jessen Hickman, MD  |  May 13, 2021

A phase 3 trial described in The New England Journal of Medicine (NEJM) highlights the potential of a C5a receptor inhibitor, avacopan, for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.1 Avacopan may potentially offer a steroid-sparing option for the treatment of this serious disease. Current Treatment of ANCA-Associated Vasculitis Morbidity and mortality from ANCA-associated vasculitis have…

Filed under:ConditionsDrug UpdatesResearch RheumVasculitis Tagged with:ANCA-Associated VasculitisavacopanGlucocorticoidsSteroids

Alisusha; Trueffelpix / shutterstock.com

3 New Vasculitis Guidelines Discussed

Ruth Jessen Hickman, MD  |  May 13, 2021

The ACR, in concert with the Vasculitis Foundation, released three new vasculitis guidelines online first in July, with a fourth slated for publication by the end of the year. These are the first ever to be produced and endorsed by the ACR and the Vasculitis Foundation. Although most of the recommendations are conditional, due to…

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:AAV FocusRheumVasculitis Foundation

FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease

Michele B. Kaufman, PharmD, BCGP  |  February 2, 2021

The FDA has approved anakinra to treat a rare autoinflammatory disease, deficiency of interleukin 1 receptor antagonist. The administration also approved a new rituximab biosimilar, Riabni, for multiple indications.

Filed under:Biologics/DMARDsDrug Updates Tagged with:anakinradeficiency of interleukin 1 receptor antagonist (DIRA)FDAFDA approvalRiabnirituximab-arrxU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences